Technical Information Report

> ANSI/AAMI/ ISO TIR13004: 2013/(R)2016

Sterilization of health care products—Radiation—
Substantiation of a selected sterilization dose: Method VD_{max}SD





Sterilization of health care products—Radiation—Substantiation of a selected sterilization dose: Method $VD_{max}^{\ \ SD}$

Approved 3 September 2013 by **A**A MI

Registered 4 October 2013 and reaffirmed 22 August 2016 by **American National Standards Institute**

Abstract: This Technical Specification describes a method for substantiating a selected sterilization dose of

17.5, 20, 22.5, 27.5, 30, 32.5 or 35 kGy that achieves a sterility assurance level (SAL) of 10^{-6} or less for radiation sterilization of health care products. This Technical Specification also specifies a method of sterilization dose audit used to demonstrate the continued effectiveness of the

substantiated sterilization dose.

Keywords: ISO 11137-2, Method VD_{max}²⁵, Method VD_{max}¹⁵

Published by

AAMI 4301 N. Fairfax Drive, Suite 301 Arlington, VA 22203-1633 www.aami.org

© 2013 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this document should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at www.aami.org or contact AAMI at 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633. Phone: +1-703-525-4890; Fax: +1-703-276-0793.

Printed in the United States of America

ISBN 1-57020-504-3

This is a preview. Click here to purchase the full publication.

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

ANSI Technical Report

This AAMI TIR has been registered by the American National Standards Institute as an ANSI Technical Report.

Publication of this ANSI Technical Report has been approved by the accredited standards developer (AAMI). This document is registered as a Technical Report series of publications according to the Procedures for the Registration of Technical Reports with ANSI. This document is not an American National Standard and the material contained herein is not normative in nature.

Comments on the content of this document should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

Gloss	eary of equivalent standards	vii
Comn	nittee representation	viii
Backg	ground of AAMI adoption of ISO TS 13004:2013	x i
Forew	vord	xi i
Introd	luction	xiii
1	Scope	1
1.1	Inclusions	
1.2	Exclusions	1
1.3	Application	1
2	Normative references	1
3	Terms and definitions	2
4	Definition and maintenance of product families for sterilization dose substantiation	_
	and sterilization dose auditing	
4.1	General	
4.2	Defining product families	
4.3	Designation of product to represent a product family	
4.3.1	Product to represent a product family	
4.3.2	Master product	
4.3.3	Equivalent product	
4.3.4 4.4	Simulated product	
4.4 4.4.1	Maintaining product families Periodic review	
4.4.1 4.4.2		
4.4.2	Modification to product and/or manufacturing processRecords	
4.4.3 4.5	Consequence of failure of sterilization dose substantiation or sterilization dose audit.	
	·	3
5	Selection and testing of product for substantiating and auditing a selected sterilization dose	40
5.1	Nature of product	
5.1 5.2	Sample item portion (SIP)	
5.2 5.3	Manner of sampling	
5.4	Microbiological testing	
5.4 5.5	Irradiation	
		_
6	Method VD _{max} ^{SD} — Substantiation of a selected sterilization dose of 17.5, 20, 22.5, 27.5, 30, 32.5, or 35 kGy	
6.1	Rationale	
6.2	Procedure for Method VD _{max} ^{SD} for multiple production batches	14
6.2.1	General	
6.2.2	Stage 1: Obtain samples of product	
6.2.3	Stage 2: Determine average bioburden	
6.2.4	Stage 3: Obtain the selected sterilization dose	
6.2.5	Stage 4: Obtain VD _{max} SD	16
6.2.6	Stage 5: Perform verification dose experiment	17
6.2.7	Stage 6: Interpretation of results	
6.2.8	Confirmatory verification dose experiment	

6.3	Procedure for Method VD _{max} ^{SD} for a single production batch	
6.3.1	Rationale	
6.3.2	General Stage 1: Obtain samples of product	
6.3.3 6.3.4	Stage 2: Determine average bioburden	
6.3. 4 6.3.5	Stage 3: Obtain the selected sterilization dose	
6.3.6	Stage 4: Obtain VD _{max} SD	
6.3.7	Stage 5: Perform verification dose experiment	
6.3.8	Stage 6: Interpretation of results	
6.3.9	Confirmatory verification dose experiment	
7	Maintaining process effectiveness	
7.1	General	
7.2	Determination of bioburden	
7.2.1	Background to frequency of determination Frequency of determination specific to Method VD _{max} ^{SD}	25
7.2.2 7.3	Sterilization dose audit	
7.3 7.3.1	Frequency	
7.3.1 7.3.2	Outcome	
7.3.3	Procedure for auditing a sterilization dose substantiated using Method VD _{max} ^{SD}	26 26
7.3.4	Failure of a sterilization dose audit	
8	Tables of values for SIP equal to 1.0 VD _{max} ^{SD} , SIP dose reduction factor and augmentation dose corresponding to applicable values of average bioburden for	20
	selected sterilization doses of 17.5, 20, 22.5, 27.5, 30, 32.5 and 35 kGy	30
9	Worked examples	
9.1	Substantiation of a selected sterilization dose of 17.5 kGy (SIP less than 1.0)	
9.2	Substantiation of a selected sterilization dose of 30 kGy (SIP equal to 1.0)	66
9.3	Stermization dose audit for a stermization dose substantiated using Method VD _{max} ,	
	the findings from which necessitated augmentation of the sterilization dose	
Bibliog	ıraphy	69
Tables		
Table 1	Nature of product items for sterilization dose substantiation and for sterilization dose auditing	10
Table 2	2 — Examples for calculation of SIP	11
Table 3	B — Upper limit of average bioburden for selection of a given sterilization dose	16
Table 4	I — Table in Clause 8 corresponding to the selected sterilization dose	16
Table 5	5 — 17.5 kGy selected sterilization dose for which the upper limit of average bioburden is 9.0	31
Table 6	6 — 20 kGy selected sterilization dose for which the upper limit of average bioburden is 45	32
Table 7	7 — 22,5 kGy selected sterilization dose for which the upper limit of average bioburden is 220	35
Table 8	3 — 27.5 kGy selected sterilization dose for which the upper limit of average bioburden is 5,000	39
Table 9	— 30 kGy selected sterilization dose for which the upper limit of average bioburden	11

Table 10 — 32.5 kGy selected sterilization dose for which the upper limit of average bioburden is 100,000	50
Table 11 — 35 kGy selected sterilization dose for which the upper limit of average bioburden is 440,000	57
Table 12 — Method VD _{max} 17.5 substantiation (SIP less than 1.0)	65
Table 13 — Method VD _{max} 30 substantiation (SIP equal to 1.0)	66
Table 14 — Sterilization dose audit following which augmentation of the sterilization dose was required (selected sterilization dose substantiated using Method VD _{max} ^{22.5})	67

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf

Committee representation

Association for the Advancement of Medical Instrumentation

Radiation Sterilization Working Group

The adoption of ISO Technical Specification (TS) 13004, as an AAMI Technical Information Report was initiated by the AAMI Radiation Sterilization Working Group, which also functions as the U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Radiation Sterilization Working Group (U.S> Sub-TAG for ISO/TC 198/WG 2, Radiation Sterilization) played an active role in developing the ISO Technical Specification.

At the time this document was published, the **AAMI Sterilization Standards Committee** had the following members:

Cochairs Victoria M. Hitchins, PhD, FDA/CDRH

Michael H. Scholla, Dupont Protection Technologies

Members Janet Prust, 3M Healthcare

Byron Lambert, Abbott Laboratories Jeff Martin, Alcon Laboratories Inc.

Ramona Conner, Association of Perioperative Registered Nurses

Patrick McCormick, Bausch & Lomb Inc.
Mark Seybold, Baxter Healthcare Corporation
Lisa Macdonald, Becton Dickinson & Company
Christopher Anderson, Boston Scientific Corporation

Trabue Bryans, BryKor LLC

Rey Lopez, Cardinal Health (MP&S)

Phil Cogdill, Covidien Kim Darnell, CR Bard Mark Smith, Getinge USA

Deborah Havlik, Hospira Worldwide Inc.

Sue Klacik, IAHCSMM

Joyce Hansen, Johnson & Johnson

Lisa Foster, Medpoint LLC

Nancy Rakiewicz, Moog Medical Devices

Joel Gorski, NAMSA

Martell Winters, Nelson Laboratories Inc.

Andrew Sharavara, Propper Manufacturing Co Inc.

Jackie Daley, Sinai Hospital of Baltimore Nancy Chobin, St Barnabas Healthcare System

Bill Young, Sterigenics International Doug Harbrecht, Sterility Assurance LLC Gerald McDonnell, Steris Corporation Colleen Landers, Timmins & District Hospital

Alternates Craig Wallace, 3M Healthcare

David McGoldrick, Abbott Laboratories

Jim Kaiser, Bausch & Lomb Inc.

Mike Sadowski, Baxter Healthcare Corporation Glenn Calvert, Becton Dickinson & Company Ralph Makinen, Boston Scientific Corporation

Dave Dion, Cardinal Health (MP&S)

Lloyd Brown, Covidien Mary Mayo, CR Bard

Karen Polkinghorne, Dupont Protection Technologies

Natalie Lind, IAHCSMM

Tom Frazar, Johnson & Johnson Patrick Polito, Moog Medical Devices Shaundrea Rechsteiner, NAMSA